HK1119707A1 - Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders - Google Patents

Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Info

Publication number: HK1119707A1
Authority: HK; Hong Kong
Prior art keywords: benz0; piperazin; derivatives; treatment; cns disorders
Prior art date: 2005-08-31

Application number

HK08113412.5A

Other languages

English (en)

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-31

Filing date

2008-12-09

Publication date

2009-03-13

2008-12-09 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2009-03-13 Publication of HK1119707A1 publication Critical patent/HK1119707A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HK08113412.5A 2005-08-31 2008-12-09 Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders HK1119707A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005251055		2005-08-31
PCT/JP2006/317704 WO2007026959A2 (en)	2005-08-31	2006-08-31	Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Publications (1)

Publication Number	Publication Date
HK1119707A1 true HK1119707A1 (en)	2009-03-13

Family

ID=37709698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK08113412.5A HK1119707A1 (en)	2005-08-31	2008-12-09	Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Country Status (26)

Country	Link
US (3)	US8071600B2 (xx)
EP (4)	EP2287161B1 (xx)
JP (1)	JP4785677B2 (xx)
KR (2)	KR20100063807A (xx)
CN (4)	CN102558140A (xx)
AR (1)	AR055203A1 (xx)
AT (4)	ATE557021T1 (xx)
AU (2)	AU2006285607B2 (xx)
BR (1)	BRPI0615140A2 (xx)
CA (1)	CA2620688C (xx)
CY (1)	CY1111671T1 (xx)
DE (1)	DE602006020294D1 (xx)
DK (1)	DK1919907T5 (xx)
ES (4)	ES2383949T3 (xx)
HK (1)	HK1119707A1 (xx)
IL (1)	IL189383A (xx)
MX (1)	MX2008002736A (xx)
MY (1)	MY145670A (xx)
PL (1)	PL1919907T3 (xx)
PT (1)	PT1919907E (xx)
RU (1)	RU2415854C2 (xx)
SG (1)	SG155180A1 (xx)
SI (1)	SI1919907T1 (xx)
TW (1)	TWI329641B (xx)
WO (1)	WO2007026959A2 (xx)
ZA (1)	ZA200801888B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE313532T1 (de)	2003-07-22	2006-01-15	Arena Pharm Inc	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
SA05260357B1 (ar)	2004-11-19	2008-09-08	ارينا فارماسيتو تيكالز ، أنك	مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
US8163746B2 (en)	2006-04-19	2012-04-24	Astellas Pharma Inc.	Azolecarboxamide derivative
USRE45336E1 (en)	2006-05-18	2015-01-13	Arena Pharmaceuticals, Inc.	Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2007136680A2 (en)	2006-05-18	2007-11-29	Arena Pharmaceuticals, Inc.	3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
BRPI0712030A2 (pt)	2006-05-18	2012-01-03	Arena Pharm Inc	formas cristalinas e processos para preparaÇço de fenil-pirazàis éteis como moduladores dos receptores de serotonina 5-h-t2a
TWI329102B (en) *	2006-08-15	2010-08-21	Nat Health Research Institutes	Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008020306A2 (en) *	2006-08-18	2008-02-21	Pfizer Products Inc.	Isoindole derivatives
TWI415845B (zh)	2006-10-03	2013-11-21	Arena Pharm Inc	用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080186971A1 (en) *	2007-02-02	2008-08-07	Tarari, Inc.	Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP1972628A1 (en) *	2007-03-21	2008-09-24	Schwarz Pharma Ag	Indolizines and aza-analog derivatives thereof as CNS active compounds
WO2008124300A1 (en) *	2007-04-10	2008-10-16	National Health Research Institutes	Hepatitis c virus inhibitors
WO2008145681A2 (en)	2007-05-31	2008-12-04	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
US7897764B2 (en) *	2007-06-08	2011-03-01	National Health Research Institutes	Thiourea derivatives
EA201070077A1 (ru) *	2007-06-29	2010-08-30	Эмори Юниверсити	Антагонисты nmda-рецепторов с нейропротективным действием
WO2009023253A2 (en)	2007-08-15	2009-02-19	Arena Pharmaceuticals Inc.	IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
EP2184272A4 (en) *	2007-08-21	2011-11-09	Shionogi & Co	PIPERAZINE DERIVATIVE
WO2009054468A1 (ja)	2007-10-24	2009-04-30	Astellas Pharma Inc.	アゾールカルボキサミド化合物又はその塩
CN101910167A (zh) *	2007-10-29	2010-12-08	先灵公司	噻唑甲酰胺衍生物及其治疗癌症
JP2011512340A (ja) *	2008-02-15	2011-04-21	エフ．ホフマン−ラロシュアーゲー	３−アルキルピペラジン誘導体及びその使用
ES2494366T3 (es) *	2008-02-22	2014-09-15	Otsuka Pharmaceutical Co., Ltd.	Compuesto de benzodiacepina y composición farmacéutica
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8198284B2 (en) *	2008-04-30	2012-06-12	National Health Research Institutes	Treatment of neurodegenerative disorders with thiourea compounds
BRPI0912362A2 (pt) *	2008-05-09	2015-10-06	Univ Emory	antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
CA2731097A1 (en) *	2008-07-15	2010-01-21	Novartis Ag	Organic compounds
JP2011529090A (ja) *	2008-07-28	2011-12-01	江蘇国華投資有限公司	アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
MX2011001846A (es) *	2008-09-01	2011-04-04	Neurosearch As	Nuevos derivados de piperidina-4-acetamida y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
HUE036506T2 (hu)	2008-10-28	2018-07-30	Arena Pharm Inc	5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére
AU2009327127C1 (en)	2008-12-19	2017-03-09	Centrexion Therapeutics Corporation	Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
US8748623B2 (en)	2009-02-17	2014-06-10	Syntrix Biosystems, Inc.	Pyridinecarboxamides as CXCR2 modulators
TWI481601B (zh) *	2009-08-21	2015-04-21	Otsuka Pharma Co Ltd	含氮化合物及藥學組成物
IN2012DN00986A (xx)	2009-08-21	2015-04-10	Otsuka Pharma Co Ltd
CA2782464C (en)	2009-12-17	2016-11-29	Boehringer Ingelheim International Gmbh	New ccr2 receptor antagonists
US8980891B2 (en)	2009-12-18	2015-03-17	Arena Pharmaceuticals, Inc.	Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011109679A2 (en) *	2010-03-05	2011-09-09	Amira Pharmaceuticals, Inc.	Inhibitors of 5-lipoxygenase
US8877745B2 (en)	2010-05-12	2014-11-04	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en)	2010-05-12	2015-02-03	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en)	2010-05-17	2014-09-23	Boehringer Ingelheim International Gmbh	CCR2 antagonists and uses thereof
WO2011147772A1 (en)	2010-05-25	2011-12-01	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists
JP5721242B2 (ja)	2010-06-01	2015-05-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ｃｃｒ２アンタゴニスト
CA2811990C (en)	2010-08-23	2023-03-21	Dean Y. Maeda	Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
CN102206214B (zh) *	2011-04-07	2014-03-12	华中科技大学	苯并吡喃酮类衍生物及其应用
WO2013010839A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Novel and selective ccr2 antagonists
AR088352A1 (es) *	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9951088B2 (en)	2012-05-09	2018-04-24	Sunovion Pharmaceuticals Inc.	D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
WO2014085208A1 (en) *	2012-11-27	2014-06-05	Merck Sharp & Dohme Corp.	2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9745284B2 (en) *	2013-03-08	2017-08-29	Merck Sharp & Dohme Corp.	2-pyridyloxy-4-ether orexin receptor antagonists
WO2014152013A1 (en) *	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	4-phenylpiperidines, their preparation and use
CN104059046B (zh) *	2013-03-18	2017-02-08	江苏恩华药业股份有限公司	黄酮类衍生物及其应用
CN104447723A (zh) *	2014-11-28	2015-03-25	瑞阳制药有限公司	7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CA2989343A1 (en)	2015-06-12	2016-12-15	Yandong Wen	Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
PT3317270T (pt)	2015-07-02	2020-08-24	Centrexion Therapeutics Corp	(4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona
JP2018520187A (ja)	2015-07-15	2018-07-26	アクソヴァントサイエンシーズゲゼルシャフトミットベシュレンクテルハフツングAxovant Sciences GmbH	神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN106749219A (zh)	2015-11-20	2017-05-31	江苏恩华药业股份有限公司	一种内酰胺类衍生物及其应用
EP3397636B1 (en)	2015-12-28	2021-08-04	Honour (R&D)	Process for the preparation of quinoline-2(1h)-one derivatives
CN112079812B (zh) *	2020-09-29	2021-08-06	浙江大学	哌唑类抗精神病药物关键中间体及其电还原方法
CN112125896B (zh) *	2020-09-29	2021-10-29	湖南省湘中制药有限公司	一种抗精神病药依匹哌唑电化学制备方法
JP2023547892A (ja) *	2020-10-27	2023-11-14	アリーナファーマシューティカルズ，インコーポレイテッド	５－ｈｔ２ａセロトニン受容体に関連する障害を処置するために有用な５－ｈｔ２ａセロトニン受容体のモジュレーターとしてのピリミジン誘導体
CN115772175A (zh) *	2021-09-07	2023-03-10	中国科学院分子细胞科学卓越创新中心	噻吩并环化合物及其制备方法和应用
AU2023211068B2 (en)	2022-01-29	2024-12-12	Suven Life Sciences Limited	Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders
CN116554145A (zh) *	2022-01-29	2023-08-08	江苏恩华药业股份有限公司	芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用
CN115521298A (zh) *	2022-05-09	2022-12-27	江苏慧聚药业股份有限公司	依匹哌唑的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2960178D1 (en)	1978-06-06	1981-04-09	Hoechst Ag	New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS5649361A (en)	1979-09-28	1981-05-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en)	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
DK611489A (da) *	1988-12-08	1990-06-09	Duphar Int Res	Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
WO1991000863A1 (en)	1989-07-07	1991-01-24	Pfizer Inc.	Heteroaryl piperazine antipsychotic agents
CA2067475C (en)	1991-05-08	2000-10-10	Yasuo Oshiro	Carbostyril derivatives and their use
US5240927A (en) *	1992-05-19	1993-08-31	Hoechst-Roussel Pharmaceuticals Incorporated	Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
US5576321A (en)	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems
EP0732332B1 (en)	1995-03-17	2001-12-19	Aventis Pharmaceuticals Inc.	Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
FR2740134B1 (fr)	1995-10-18	1998-01-09	Pf Medicament	Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EP0934932A4 (en)	1996-08-22	2002-06-26	Meiji Seika Kaisha	CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
FR2761068B1 (fr)	1997-03-20	1999-04-23	Synthelabo	Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
ATE303987T1 (de)	1999-05-24	2005-09-15	Mitsubishi Pharma Corp	Phenoxypropylamin-derivate
AR027134A1 (es) *	1999-12-30	2003-03-12	Lundbeck & Co As H	Derivados de indol.
AR027133A1 (es) *	1999-12-30	2003-03-12	Lundbeck & Co As H	Derivados de heteroarilo, su preparacion y uso.
IL157412A0 (en)	2001-02-16	2004-03-28	Aventis Pharmaceuticals Inc Av	Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
AU2002322051A1 (en)	2001-06-07	2002-12-16	Wayne State University	Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity
CA2451229C (en) *	2001-06-29	2009-02-10	H. Lundbeck A/S	Indole derivatives
EP1546143A1 (en) *	2002-09-17	2005-06-29	Warner-Lambert Company LLC	Heterocyclic substituted piperazines for the treatment of schizophrenia
AU2003260882A1 (en)	2002-09-26	2004-04-19	Warner-Lambert Company Llc	Heterocyclic substituted piperazines for the treatment of schizophrenia
GB0227240D0 (en) *	2002-11-21	2002-12-31	Glaxo Group Ltd	Compounds
US7160888B2 (en)	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物

2006
- 2006-08-30 TW TW095132016A patent/TWI329641B/zh not_active IP Right Cessation
- 2006-08-30 AR ARP060103780A patent/AR055203A1/es unknown
- 2006-08-31 KR KR1020107009007A patent/KR20100063807A/ko active IP Right Grant
- 2006-08-31 AT AT10188671T patent/ATE557021T1/de active
- 2006-08-31 ES ES10188683T patent/ES2383949T3/es active Active
- 2006-08-31 ZA ZA200801888A patent/ZA200801888B/xx unknown
- 2006-08-31 EP EP10188671A patent/EP2287161B1/en not_active Not-in-force
- 2006-08-31 CA CA2620688A patent/CA2620688C/en not_active Expired - Fee Related
- 2006-08-31 ES ES10188671T patent/ES2383948T3/es active Active
- 2006-08-31 WO PCT/JP2006/317704 patent/WO2007026959A2/en active Application Filing
- 2006-08-31 CN CN2011104410868A patent/CN102558140A/zh active Pending
- 2006-08-31 AT AT06797580T patent/ATE499369T1/de active
- 2006-08-31 DK DK06797580.5T patent/DK1919907T5/da active
- 2006-08-31 BR BRPI0615140-0A patent/BRPI0615140A2/pt not_active IP Right Cessation
- 2006-08-31 JP JP2006235401A patent/JP4785677B2/ja not_active Expired - Fee Related
- 2006-08-31 MX MX2008002736A patent/MX2008002736A/es active IP Right Grant
- 2006-08-31 PT PT06797580T patent/PT1919907E/pt unknown
- 2006-08-31 EP EP10188683A patent/EP2287162B1/en not_active Not-in-force
- 2006-08-31 AT AT10188688T patent/ATE549330T1/de active
- 2006-08-31 CN CN2011104414290A patent/CN102850336A/zh active Pending
- 2006-08-31 ES ES10188688T patent/ES2382445T3/es active Active
- 2006-08-31 PL PL06797580T patent/PL1919907T3/pl unknown
- 2006-08-31 AT AT10188683T patent/ATE557022T1/de active
- 2006-08-31 KR KR1020087004418A patent/KR101008873B1/ko not_active IP Right Cessation
- 2006-08-31 AU AU2006285607A patent/AU2006285607B2/en not_active Ceased
- 2006-08-31 CN CN2006800320431A patent/CN101258147B/zh not_active Expired - Fee Related
- 2006-08-31 SI SI200630973T patent/SI1919907T1/sl unknown
- 2006-08-31 ES ES06797580T patent/ES2362961T3/es active Active
- 2006-08-31 SG SG200905174-9A patent/SG155180A1/en unknown
- 2006-08-31 RU RU2008112224/04A patent/RU2415854C2/ru not_active IP Right Cessation
- 2006-08-31 CN CN2011104423270A patent/CN102702182A/zh active Pending
- 2006-08-31 US US11/991,146 patent/US8071600B2/en not_active Expired - Fee Related
- 2006-08-31 MY MYPI20080316A patent/MY145670A/en unknown
- 2006-08-31 EP EP06797580A patent/EP1919907B9/en not_active Not-in-force
- 2006-08-31 DE DE602006020294T patent/DE602006020294D1/de active Active
- 2006-08-31 EP EP10188688A patent/EP2284169B1/en not_active Not-in-force
2008
- 2008-02-07 IL IL189383A patent/IL189383A/en not_active IP Right Cessation
- 2008-12-09 HK HK08113412.5A patent/HK1119707A1/xx not_active IP Right Cessation
2010
- 2010-02-01 AU AU2010200362A patent/AU2010200362A1/en not_active Ceased
2011
- 2011-04-18 CY CY20111100400T patent/CY1111671T1/el unknown
- 2011-10-11 US US13/270,544 patent/US8598162B2/en not_active Expired - Fee Related
2013
- 2013-09-20 US US14/032,568 patent/US20140031334A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL189383A (en)	2013-03-24
ES2383948T3 (es)	2012-06-27
RU2008112224A (ru)	2009-10-10
ES2362961T3 (es)	2011-07-15
CN102702182A (zh)	2012-10-03
TWI329641B (en)	2010-09-01
US8598162B2 (en)	2013-12-03
WO2007026959A3 (en)	2007-08-16
JP4785677B2 (ja)	2011-10-05
AR055203A1 (es)	2007-08-08
EP2284169A1 (en)	2011-02-16
KR101008873B1 (ko)	2011-01-19
AU2010200362A1 (en)	2010-02-18
TW200800937A (en)	2008-01-01
PT1919907E (pt)	2011-03-23
JP2007091733A (ja)	2007-04-12
DK1919907T3 (da)	2011-04-18
MY145670A (en)	2012-03-15
BRPI0615140A2 (pt)	2010-01-12
CY1111671T1 (el)	2015-10-07
CN102558140A (zh)	2012-07-11
ES2383949T3 (es)	2012-06-27
SI1919907T1 (sl)	2011-05-31
ATE549330T1 (de)	2012-03-15
ES2362961T9 (es)	2012-02-13
DK1919907T5 (da)	2011-09-12
CN102850336A (zh)	2013-01-02
US20120028920A1 (en)	2012-02-02
ATE499369T1 (de)	2011-03-15
AU2006285607A1 (en)	2007-03-08
CA2620688A1 (en)	2007-03-08
ES2382445T3 (es)	2012-06-08
ZA200801888B (en)	2009-07-29
CN101258147B (zh)	2012-03-21
PL1919907T3 (pl)	2011-07-29
EP2287161A1 (en)	2011-02-23
EP1919907B1 (en)	2011-02-23
US20090264404A1 (en)	2009-10-22
ATE557021T1 (de)	2012-05-15
EP2284169B1 (en)	2012-03-14
US20140031334A1 (en)	2014-01-30
EP1919907B9 (en)	2012-01-18
SG155180A1 (en)	2009-09-30
EP2287162B1 (en)	2012-05-09
EP2287162A1 (en)	2011-02-23
CN101258147A (zh)	2008-09-03
WO2007026959A2 (en)	2007-03-08
MX2008002736A (es)	2008-03-26
KR20080033446A (ko)	2008-04-16
US8071600B2 (en)	2011-12-06
RU2415854C2 (ru)	2011-04-10
EP2287161B1 (en)	2012-05-09
ATE557022T1 (de)	2012-05-15
IL189383A0 (en)	2008-06-05
AU2006285607B2 (en)	2010-02-25
KR20100063807A (ko)	2010-06-11
DE602006020294D1 (de)	2011-04-07
EP1919907A2 (en)	2008-05-14
CA2620688C (en)	2014-03-25

Publication	Publication Date	Title
HK1119707A1 (en)	2009-03-13	Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders
TW200716619A (en)	2007-05-01	Heterocyclic compound
HK1101178A1 (en)	2007-10-12	Alkynyl derivatives as modulators of metabotropic glutamate receptors
GB0325956D0 (en)	2003-12-10	Novel compounds
MY141255A (en)	2010-03-31	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE388958T1 (de)	2008-03-15	4'-c-substituierte 2-haloadenosinderivate
HK1107227A1 (en)	2008-04-03	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2007062999A3 (en)	2007-07-26	1,5-substituted indol-2-yl amide derivatives
TW200718692A (en)	2007-05-16	Dihydrobenzofuran derivatives and uses thereof
AP1753A (en)	2007-07-18	Thiophene derivatives as antiviral agents for flavvivirus infection
DE602004029242D1 (en)	2010-11-04	Pyrazolamidverbindungen
ATE339409T1 (de)	2006-10-15	Trizyklische verbindungen
EP1719761A4 (en)	2007-10-10	NEW HETEROCYCLIC CONNECTION
MX2010001566A (es)	2010-03-15	Derivado de aminopirazolamida.
MY141784A (en)	2010-06-30	Phenylpyridylpiperazine compounds
GB0412314D0 (en)	2004-07-07	Compounds
WO2008063548A3 (en)	2009-01-08	5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents
MY140963A (en)	2010-02-12	Phenylpyridylpiperazine compounds
PL1976525T3 (pl)	2011-05-31	Pochodne piperydyny oraz piperazyny
PL1603877T3 (pl)	2009-05-29	Nowe pochodne aminopirydyny jako antagoniści mGluR5
AU6017800A (en)	2001-02-13	Novel amide derivatives
EP1557407A4 (en)	2006-11-15	NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF
EP1614684A4 (en)	2007-09-05	DIAMIDE DERIVATIVE, METHOD OF MANUFACTURE AND ANTIOXIDATION MEDICAMENTS
TH92869A (th)	2008-12-30	สารประกอบเฮเทโรไซคลิค
EP1709966A4 (en)	2009-04-29	PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION

Legal Events

Date	Code	Title	Description
2012-11-30	CHRG	Changes in the register	Free format text: DELETION OF INVENTORS:
2017-03-24	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20160831